In the published article, there was an error in the Funding statement. The correct Funding statement appears below.
“This work was funded by the European Regional Development Fund (ERDF) through COMPETE 2020, Portugal 2020 and by FCT (Fundação para a Ciência e Tecnologia), ([POCI-01-0145-FEDER-030985 and POCI-01-0145-FEDER-016385]) and by FCT/Ministério da Ciência, Tecnologia e Inovação in the framework of individual funding [CEECINST/00091/2018] to DN and by QREN funds through the project ClinUCX (QREN 30196) and individual fellowships: [PD/BD/127997/2016] to TL, [SFRH/BD/144490/2019] to RG [SFRH/BD/111799/2015] to VS-P. The funding bodies other than ECBio had no role in design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.”
Also, the role of funder ECBio S.A. was missing from the Conflict of interest statement. The correct Conflict of interest statement appears below.
“HC and PC were shareholders of ECBio S.A. JS and RB were employees of ECBio S.A.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors declare that this study received funding from ECBio S.A. The funder had the following involvement in the study: provided all cell batches required for the studies.”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
mesenchymal stromal (or stem) cells, Wharton’s jelly, myocardial infarction, regeneration/repair, umbilical cord matrix derived mesenchymal stromal cells (hUCM-MSCs), cell therapy, donor variability, cardiac fibrosis
Citation
Laundos TL, Vasques-Nóvoa F, Gomes RN, Sampaio-Pinto V, Cruz P, Cruz H, Santos JM, Barcia RN, Pinto-do-Ó P and Nascimento DS (2023) Corrigendum: Consistent long-term therapeutic efficacy of human umbilical cord matrix-derived mesenchymal stromal cells after myocardial infarction despite individual differences and transient engraftment. Front. Cell Dev. Biol. 11:1265005. doi: 10.3389/fcell.2023.1265005
Received
21 July 2023
Accepted
26 July 2023
Published
18 August 2023
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
11 - 2023
Updates
Copyright
© 2023 Laundos, Vasques-Nóvoa, Gomes, Sampaio-Pinto, Cruz, Cruz, Santos, Barcia, Pinto-do-Ó and Nascimento.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Diana S. Nascimento, dsn@ineb.up.pt
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.